Skip To Main Content
This website contains promotional content and is intended for Healthcare Professionals in the Republic of Ireland only. Adverse event reporting can be found at the bottom of the page
Campus
Campus
  • Article
  • Source: Campus Sanofi

What are the benefits of rosuvastatin?

Sanofi : Author
Editorial Team

STELLAR Trial1

Rosuvastatin reduced LDL-C more effectively across dose ranges than atorvastatin1

Drug tolerability was similar across treatments1

VOYAGER Meta-analysis2

Each doubling of statin dose results in approximately a 5-6% greater reduction in LDL-C2

Changes in lipid parameters with increasing statin doses2

A Retrospective cohort analysis3

Intensive lipid lowering is well established in reducing mortality3

Adjusted mortality curves for different intensities of statin therapy (Primary Endpoint)

Low-intensity statin therapy:

Fluvastatin, 20 to 40 mg, lovastatin, 20 mg, simvastatin, 10 mg, pitavastatin, 1 mg, and pravastatin, 10 to 20 mg.

Moderate-intensity statin therapy:

Atorvastatin, 10 to 20 mg, fluvastatin, 40 mg twice a day or 80 mg once a day, lovastatin, 40 mg, pitavastatin, 2 to 4 mg, pravastatin, 40 to 80 mg, rosuvastatin, 5 to 10 mg, and simvastatin, 20 to 40 mg.

High-intensity statin therapy: 

Atorvastatin, 40 to 80 mg, or rosuvastatin, 20 to 40 mg.

Image adapted from Rodriguez et al (2017)3

Study design3: A retrospective cohort analysis was conducted of patients aged 21 to 84 years with ASCVD treated in the Veterans Affairs health care system from April 1, 2013, to April 1, 2014.

JUPITER Trial4

Rosuvastatin delivers a reduction in CV risk4

JUPITER4: 17,802 apparently healthy men and women with LDL-C < 3.4 mmol per litre and high-sensitivity C-reactive protein < 2.0 mg per litre or higher randomised to rosuvastatin 20 mg daily (n=8,901), or placebo (n=8,901)

Total numbers of reported serious adverse events were similar in the rosuvastatin and placebo groups (1352 and 1377, respectively; P = 0.60)4

A risk-benefit analysis5

Compared with other statins, the benefit-risk profile of rosuvastatin appears to be favourable5

Elevations in ALT or CK and LDL-C reduction5

  1. Jones PH, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152–60.
  2. Nicholls SJ, et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010; 105(1): 69-76.
  3. Rodriguez F, et al. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017; 2(1): 47-54.
  4. Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008; 359: 2195-2207. 
  5. Brewer HB, et al. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003; 92(4B): 23K-9K.

ALT: alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; CK: creatine kinase; CV, cardiovascular; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; LS, least squares; mg, milligram; ARR, absolute risk reduction; STELLAR, Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin; ULN: upper limit of normal.

Our Products

Suvezen® Product Page

Click here for Prescribing Information

 

MAT-IE-2300173 (v3.0)
Date of preparation: April 2024

MAT-IE-2300207 (v2.0) Date of Preparation: May 2024